Chlamydia trachomatis (chlamydia) and Neisseria gonorrhoeae (gonorrhea) are the most prevalent bacterial sexually transmitted infections (STIs) worldwide. If left untreated, chlamydia and gonorrhea infections could lead to long-term complications in women such as ectopic pregnancy, pelvic inflammatory disease, and eventually infertility [1] . As a result, STIs place a large burden on women. International control programs focus on urogenital infections in women. However, chlamydia and gonorrhea can also infect the anorectum in women. Prevalence of anorectal chlamydia in women ranges from 7% to 17%, whereas for gonorrhea this figure is 0-3% [2] . The direct and indirect clinical impacts of anorectal infections in terms of morbidity are largely unknown. Several studies in men who have sex with men report cases of proctitis [3] , or highlight the higher risk of human immunodeficiency virus (HIV) transmission [4] . However, studies about the clinical impact of anorectal infections for women are scarce [2] . As the majority of chlamydia and gonorrhea infections are (at least initially) asymptomatic in women, effective control strategies are difficult to design for this group. Current international guidelines advocate selective symptom-and sexual history-based anorectal chlamydia and gonorrhea testing in women [5] -that is, anorectal testing on indication (ie, after the self-report of anal sex and/or symptoms). Previous studies mention anorectal chlamydia and gonorrhea detection among women who did not report anal sex [6] [7] [8] [9] [10] [11] [12] [13] . The majority of women with an anorectal chlamydia infection also have a concurrent urogenital infection [2] . Therefore, based on mathematical models, autoinoculation has been postulated as a possible reason for anorectal chlamydia detection in women [14] . It is unknown whether autoinoculation would play a role in anorectal gonorrhea in women, as very few studies have screened for anorectal gonorrhea in women who did not report anal sex [8, 9, 15] . Altogether, anorectal chlamydia and gonorrhea infections in women pose a challenge for public health practice.
This study assesses whether current testing guidelines contribute to appropriate chlamydia and gonorrhea control strategies. This study provides insight by using the world's largest dataset to date including women who were routinely universally tested for genital and anorectal chlamydia and gonorrhea, and offers recommendations for an optimal testing policy to manage anorectal infections in women.
METHODS

Study Population and Definitions
From January to December 2015, all women (n = 1012) aged ≥16 years who attended the North Limburg Public Health Service's STI clinic were routinely universally tested for urogenital and anorectal chlamydia and gonorrhea. Of all women visiting the STI clinic in the study period, only 54 (5.4%) were not tested at the anorectal site; of these, 37 women (69%) attended the STI clinic just after the start of the study in January when protocols were not yet fully in place. Five women were excluded because of age <16 years, and 3 women were excluded because they were tested for anorectal chlamydia but not for anorectal gonorrhea. In total, 950 consultations with 832 women were used for the analyses. Data were collected on demographics and sexual behavior in the past 6 months using an electronic patient registry. Prostitution was defined as receiving money for sex in the past 6 months. Swingers were defined as women who were part of a male-female couple who had sex as a couple with other male-female couples and their self-identified heterosexual sex partners. The definition of "anal symptoms" included 1 or more of the following: rectal discharge, bleeding, pain, redness, burning sensation, or itching.
Study Procedures
The specimens tested consisted of self-collected vaginal swabs and anorectal swabs, which studies have proven to be a generally acceptable, valid, and feasible approach [16] . Trained study nurses provided women with oral instructions about how to take separate self-collected vaginal and rectal swabs. For the vaginal swab, the patient was instructed to insert the swab 2.5 cm into the vagina, rotate it for 5-10 seconds, and then place it in a capped tube to avoid potential contamination. This procedure was repeated in the anus for the anorectal swab. Specimens were processed at a regional laboratory using the Aptima Combo 2 chlamydia/gonorrhea assay (Hologic GenProbe Inc, San Diego, California). Here we focus on chlamydia and gonorrhea testing, although women's serum was also tested for Treponema pallidum hemagglutination and HIV according to the manufacturer's protocol. The results for all women who were tested for HIV or syphilis (HIV, 45% tested [n = 430]; syphilis, 45% tested [n = 428]) were negative. One woman had previously been treated for syphilis.
Statistical Analysis
Women were assigned to the category "with indication" when they reported having had anal sex and/or anal symptoms in the past 6 months. Women "without indication" did not report having had anal sex or symptoms in the past 6 months. In 8% of consultations (n = 75), data on anal sex were missing; for anal symptoms this figure was 0.1% (n = 1). These women were placed in the "missing indication" category. Prevalence of chlamydia and gonorrhea at urogenital and anorectal sites was calculated by dividing the number of positive tests by the total number of tests, multiplied by 100. Demographic and behavioral variables (described below) were compared between the 3 indication categories by means of χ 2 tests, using "without indication" as a reference. To explore the anatomic site distribution of chlamydia and gonorrhea, 2 mutually exclusive categories were constructed. The first category included all urogenital and anorectal infections: anorectal-only infections, concurrent urogenital and anorectal infections, and urogenital-only infections. The second category included solely anorectal infections: anorectal-only infections and concurrent urogenital and anorectal infections. Univariable and multivariable logistic regression analyses were used to identify determinants associated with anorectal chlamydia and gonorrhea, and anorectal-only chlamydia. Data values were too low for analyses on anorectal-only gonorrhea. The variables tested were age (≤21 years, 22-25 years, and ≥26 years), nationality, number of sex partners in the past 6 months (1, 2-3, and ≥4), prostitution and swinger status, urogenital symptoms, anorectal symptoms, and the self-report of anal sex (yes, no, missing). The multivariable models were adjusted for anorectal symptoms and the self-report of anal sex. Analyses were performed using SPSS software version 21.0.0 (IBM, Somers, New York). The Medical Ethics Committee of Maastricht University (identification number 11-4-108) approved the study.
RESULTS
Of the 950 women, the median age was 23 years (interquartile range [IQR], 21-28 years) and the majority (94% [n = 889]) had Western nationality. Women reported a median of 2 sex partners in the past 6 months (IQR, 1-4). In total, 7.6% (n = 72) were prostitutes and 11.1% were swingers (n = 105). An indication was reported by 19.5% (n = 185) of women; only 3 women (1.6%) with indication reported both anal sex and anal symptoms. The characteristics of the study population are described in (Table 1 ). In 15.3% (n = 145) of consultations, a diagnosis of at least urogenital or anorectal chlamydia or gonorrhea was made. Of all urogenital and anorectal infections, 88.3% (n = 128) were chlamydia-only infections (no gonorrhea present), 4.8% (n = 7) were gonorrhea-only infections (no chlamydia present), and 6.9% (n = 10) were chlamydia and gonorrhea coinfections.
Chlamydia Positivity and Associated Determinants
Overall urogenital chlamydia positivity was 10.9% (n = 104) and overall anorectal chlamydia positivity was 13.4% (n = 127). Positivity for chlamydia per indication category is presented in (Table 2) , ranging between 6.6% and 14.1% for the indication categories. Of all women with anorectal chlamydia, 72.4% (n = 92) were without indication, 20.5% (n = 26) were with indication, and 7.1% (n = 9) were missing indication. Self-report of anal sex and anal symptoms was not associated with anorectal chlamydia infections (odds ratio 
Gonorrhea Positivity and Associated Determinants
Overall urogenital gonorrhea positivity was 1.5% (n = 14) and anorectal gonorrhea positivity was 1.3% (n = 12). Positivity for gonorrhea ranged between 0.6% and 1.2% for women without indication, between 3.2% and 3.8% for women with indication, and between 0 and 1.3% for women with missing indication (Table 2) . Of all women with anorectal gonorrhea, 33.3% (n = 4) were without indication, 58.3% (n = 7) were with indication, and 8.3% (n = 1) were missing indication. Independent determinants for anorectal gonorrhea were self-report of anal sex and anal symptoms (OR, 3.3 [95% CI, 1.01-10.7], P = .05 and OR, 14.5 [95% CI, 2.8-75.0], P = .001, respectively) ( Table 2) .
Anatomic Site Distribution of Chlamydia
The anatomic site distribution of urogenital and anorectal chlamydia and gonorrhea is presented in ( Table 2 ). 
Anatomic Site Distribution of Gonorrhea
The proportion of anorectal-only infections was similar in women with indication (25.0% [n = 2]) compared to women without or missing indication (20.0% [n = 1]), though it should be noted that data values were small (Table 2) . Among all anorectal gonorrhea cases, 75.0% (9/12) were concurrent urogenital and anorectal infections, and 25.0% (3/12) were anorectal-only infections.
DISCUSSION
This study informs the optimal control strategy for anorectal chlamydia and gonorrhea by using a large dataset of women who were routinely universally tested for urogenital and anorectal chlamydia and gonorrhea. Current anorectal testing guidelines (ie, based on indication) are likely suboptimal for managing anorectal chlamydia; this is evident from our findings revealing a high prevalence of anorectal chlamydia infections in women without indication, with 1 in 5 cases being anorectal-only infections. Current guidelines could be appropriate for anorectal gonorrhea, as such a strategy would only miss very few anorectal gonorrhea infections, and having an indication for testing was independently associated with anorectal gonorrhea. Age was the only determinant associated with anorectal chlamydia, as young women more often had an anorectal chlamydia infection, whereas older women more often had an anorectal-only chlamydia infection. Other studies have found associations between anorectal-only chlamydia and non-Western nationality [17] , not being named as a contact to an STI [6] , and never using drugs [6] .
Chlamydia prevalence was similar between women with indication and women without indication. Therefore, the current testing policy of selective testing on indication misses more than half of anorectal chlamydia infections in women [10, 18] . The majority of women with anorectal chlamydia had concurrent urogenital chlamydia. Hence, 61% (n = 78) of the missed anorectal infections could be coincidentally treated with azithromycin. However, several studies report lower [19, 20] or equal effectiveness [21] of azithromycin for anorectal chlamydia infections. Some countries such as the United Kingdom and the Netherlands recommend doxycycline as a first-line treatment for anorectal chlamydia [22, 23] , while others recommend both azithromycin and doxycycline as first-line treatments for anorectal chlamydia [5] . A double-blind randomized controlled trial is necessary to inform treatment policy for chlamydia [2, 10, 24] .
The proportion of anorectal-only chlamydia infections was substantial in this study: 38% (n = 11) in women with indication and 19% (n = 19) in women without indication. The latter 19% would be completely missed in practice, because they would not be tested or coincidentally treated for the infection. In this study, only 20% (26/127) of anorectal chlamydia infections would be adequately treated according to Dutch guidelines, due to absent or missing data on self-reported anal sex or symptoms, or absence of a urogenital infection. When translating these results to women visiting the STI clinic, the population prevalence of anorectal-only chlamydia in women without indication is 3% (19/689). The proportion of anorectal-only chlamydia infections was higher than previous studies in the Netherlands (4%) [10] and Australia [11] , but comparable to other studies from our group on high-risk groups (15%-19%) [25] as well as studies from South Africa (10%) [8] , Scandinavia (7%-19%) [7, 13] , and Canada (18%-47%) [6] , and other large studies using selective testing on indication (4%-25%) [2, 17, 18, [26] [27] [28] . Undetected or inadequately treated anorectal chlamydia might act as a reservoir, enabling ongoing transmission. Studies suggest that women can get an anorectal infection through transmission by autoinoculation from vaginal secretions [2] . The urogenital tract can possibly be reinfected by autoinoculation. However, this theory is not supported by rigorous data, and prospective studies using behavioral questionnaires and multiple sampling times are needed [29] .
Prevalence of anorectal gonorrhea was comparable to other studies using routine universal screening in women [8] and other large studies using selective testing on indication (0-3%) [9, 18, [26] [27] [28] . Anorectal gonorrhea positivity was 3.8% (n = 7) in women with indication, 0.6% (n = 4) in women without indication, and 1.3% (n = 1) in women with missing indication. The self-report of anal sex and symptoms was independently associated with anorectal gonorrhea. However, 5 of 12 women with anorectal gonorrhea did not have an indication or had missing data on this, and thus in practice would not have been tested at the anorectal site. Because treatment for anorectal gonorrhea is the same as treatment for urogenital gonorrhea, all but 1 (which is 89%) would have been coincidentally treated for their urogenital infections in this study. This indicates that current selective testing could be an appropriate control strategy for anorectal gonorrhea detection in women, missing very few cases. Still, the missed cases amount to 11% (1 of the 5 women had an anorectal-only gonorrhea infection), and these women would be left untested and untreated. Other studies using routine universal screening either found higher rates of anorectal-only gonorrhea in women (40%) [8] , did not find any anorectal gonorrhea [10] , or found comparable results; 20%-28% of anorectal gonorrhea infections were anorectal only [25] . The absolute number of anorectal gonorrhea infections in this study was 12, and therefore results should be interpreted carefully. Additionally, extragenital gonorrhea testing is important to monitor gonorrhea resistance as well. In practice, chlamydia and gonorrhea testing often occurs simultaneously by using a combined nucleic acid amplification test (NAAT). Therefore, when extragenital testing is advocated by guidelines, both the chlamydia and gonorrhea test results will be available. Thus, when combined NAAT assays are used in the selective testing on indication protocol, half of all anorectal chlamydia infections and almost all gonorrhea cases will be diagnosed. Part of the missed chlamydia cases will be coincidentally treated as urogenital infections. Given a testing protocol with routine universal anorectal screening, all chlamydia and gonorrhea infections will logically be diagnosed and optimally treated.
The participation rate of the study was high (94%), meaning the results are therefore highly representative of the regular STI clinic attendees and probably generalizable to female STI clinic populations in developed countries. Prevalence of anorectal chlamydia (13.4%) and gonorrhea (1.3%) were similar, as found in other studies (chlamydia, 5%-15%; gonorrhea, 0-3%) [2] , confirming this generalizability. Moreover, our high response rate confirms the high acceptability and feasibility for routine anorectal screening in women using self-taken anal swabs as found earlier, including women who did not report anal sex or symptoms [10] . A general limitation is the reliability of self-reported behavior in a sexual history. However, 19% of women reported having had anal sex, and this is probably a realistic estimation as this proportion is comparable to that found in a large recent study in the United States [30] . Bias due to using a recall period that is too short to capture the behavioral exposure could be possible. Infections may have been acquired before the beginning of the screening interval, and these could have gone unnoticed due to their asymptomatic nature and lack of extragenital testing in women.
In conclusion, routine universal anorectal screening in women who do not report anal sex or symptoms is feasible and highly acceptable. Anorectal chlamydia prevalence was high in women visiting the STI clinic (13%). Current selective testing on indication could be a suboptimal control strategy for anorectal chlamydia in women. In total, 80% (n = 101) of anorectal chlamydia infections would not have been tested for, 61% (n = 78) might have been coincidentally treated with azithromycin, and 18% (n = 23, anorectal-only) would not have been treated. Selective testing could be an appropriate control strategy for anorectal gonorrhea in women, as the self-report of anal sex and anal symptoms were independent predictors for anorectal gonorrhea, and treatment is equal for urogenital and anorectal gonorrhea. Nevertheless, a few infections would still be missed and resistance monitoring should therefore be taken into account. 
